Comparison between 200 μg and 800 μg of vaginal misoprostol for cervical ripening before operative hysteroscopy: A randomized controlled trial.

Objective: To compare between 200 and 800 μg of vaginal misoprostol for cervical ripening before operative hysteroscopy.

Methods: Quadruple-blind randomized clinical trial conducted between November 2019 and September 2020 involving 76 patients undergoing cervical dilatation before surgical hysteroscopy at teaching hospitals in Pernambuco, Brazil. Women received the vaginal misoprostol dosage of 200 or 800 μg,10-12 h before operative hysteroscopy.

Frequency and Factors Associated with Urinary Incontinence in Pregnant Adolescents: A Cross-Sectional Study.

Study Objective: To determine the overall frequency of urinary incontinence in pregnant adolescents, focusing particularly on the presence of symptoms of stress urinary incontinence (SUI) and coital incontinence (CI), and to describe the biological, sociodemographic, clinical, urinary, reproductive, sexual, and lifestyle factors associated with incontinence.

Design: A cross-sectional, descriptive study.

Setting: The outpatient clinic for high-risk pregnancies at the Instituto de Medicina Integral Prof.

Maternal and perinatal outcomes in women with and without hypertensive syndromes submitted to induction of labor with misoprostol.

Objectives: To determine maternal and perinatal outcomes according to the mode of delivery in normotensive and hypertensive women bearing a live, full-term fetus, who were submitted to labor induction with misoprostol.

Methods: Retrospective cohort study. The endpoints were tachysystole, uterine hyperstimulation, indications for cesarean section, severe maternal morbidity, side effects, maternal death, 1st/5th minute Apgar, neonatal death, requirement for neonatal intensive care, and birth weight (grams).

Native vaginal tissue repair for genital prolapse surgical treatment: a minimum of 30 months of results.

Objective: The aim of this study was to assess the impact of using native vaginal tissue repair as a surgical treatment for pelvic organ prolapse (POP) on quality of life using validated questionnaires.

Study Design: Fifty-one women underwent surgical POP repair. All of the women were evaluated by physical examination using the POP-Q, ICIQ-VS and P-QoL questionnaires prior to surgery as well as six and at least 30 months after surgery.

Maternal near miss in the intensive care unit: clinical and epidemiological aspects.

Objective: To analyze the epidemiological clinical profile of women with maternal near miss according to the new World Health Organization criteria.

Methods: A descriptive cross-sectional study was conducted, in which the records of patients admitted to the obstetric intensive care unit of a tertiary hospital in Recife (Brazil) over a period of four years were analyzed. Women who presented at least one near miss criterion were included.

Factors associated with vaginal delivery in hypertensive and normotensive pregnant women submitted to labor induction with misoprostol: a cohort study.

Objective: To determine the factors associated with vaginal delivery in hypertensive and normotensive pregnant women submitted to induction of labor with misoprostol.

Methods: A cohort study.

Results: The factors associated with vaginal delivery in both normotensive and hypertensive women were, respectively, Bishop score ≥ 4 (OR = 1.

Fascial surgical repair for vaginal prolapse: effect on quality of life and related symptoms.

Objective: The aim of this study was to evaluate the impact of surgical treatment for pelvic organ prolapse (POP) on quality of life and on bladder, vaginal and bowel symptoms using validated questionnaires such as the prolapse quality of life questionnaire (P-QoL).

Study Design: Sixty-five women underwent surgical POP repair. All were evaluated by physical examination and by the use of ICIQ-VS and P-QoL questionnaires before surgery as well as three and six months after surgery.

Titrated oral misoprostol solution versus vaginal misoprostol for labor induction.

Objective: To determine the efficacy and safety of a titrated oral misoprostol solution compared with vaginal misoprostol tablets for labor induction.

Methods: A randomized, triple-blind, multicenter clinical trial was conducted between March 2010 and June 2011. Women with a single gestation (n=200) were randomized to receive a titrated oral misoprostol solution (initial misoprostol dose 20 μg/hour; dose increased by 20 μg/hour every 6 hours up to 80 μg/hour for a maximum of 48 doses) or vaginal misoprostol tablets (25 μg of misoprostol every 6 hours for a maximum of 8 doses).

Fetal and neonatal deaths among cases of maternal near miss.

Objective: To determine the prevalence of fetal and neonatal deaths among patients with maternal near miss and the factors associated with this fatal outcome.

Methods: The authors conducted a descriptive, cross-sectional, analyzing medical records of patients admitted to the ICU of a tertiary obstetric Recife (Brazil), between January 2007 and December 2010, who had at least one criterion of near miss defined by WHO. Statistical analysis was performed with Epi-Info 3.

Misoprostol prior to inserting an intrauterine device in nulligravidas: a randomized clinical trial.

Study Question: How effective is the vaginal administration of misoprostol in dilating the cervix prior to inserting an intrauterine device (IUD) in nulligravidas?

Summary Answer: The use of misoprostol at a dose of 400 µg administered vaginally 4 h prior to IUD insertion increased the ease of insertion and reduced the incidence of pain during the procedure, although the frequency of cramps increased following misoprostol use.

What Is Known And What This Paper Adds: Misoprostol has been widely used in Obstetrics and Gynecology; however, its usefulness and efficacy in facilitating IUD insertion in nulligravidas have yet to be established. The present study shows that the benefits of misoprostol use prior to IUD insertion include facilitating insertion and reducing pain during the procedure; therefore, weighing up the benefits encountered against the only negative side effect (cramps prior to insertion), these results suggest that misoprostol use should become standard practice to facilitate IUD insertion in nulligravidas.

[Antihypertensive treatment in pregnancy].

Pregnancy hypertensive disorders represent a frequent gestational pathology. It is one of the most important causes of maternal demise and perinatal morbidity/mortality in the world. Antihypertensive treatment is part of a vast therapeutic arsenal used for prevention of severe complications.

[Transdermal nitroglycerin versus oral nifedipine administration for tocolysis: a randomized clinical trial].

Purpose: to compare the effectiveness of transdermal nitroglycerin with oral nifedipine in the inhibition of preterm delivery.

Methods: a clinical essay has been performed with 50 women in preterm delivery, randomly divided into two groups, 24 receiving oral nifedipine (20 mg), and 26, transdermal nitroglycerin (10 mg patch). Patients with a single gestation, between the 24th and the 34th weeks and diagnosis of preterm delivery were selected.

[Chlamydia infection in patients with and without cervical intra-epithelial lesions].

Objectives: To determine the frequency of Chlamydia trachomatis infection in patients with and without intraepithelial cervical lesions attended at specialized ambulatory in Recife (2007) and its association with biologic and demographic variables, habits, reproductive, clinical and gynecologic characteristics.

Methods: A cross-sectional study was conducted including 70 women (35 with cytological cervical lesions and 35 with normal smears). Colposcopy and biopsy when necessary were performed and Chlamydia infection was determined by direct immunofluorescence.

Vaginal misoprostol prior to diagnostic hysteroscopy in patients of reproductive age: a randomized clinical trial.

Study Objective: To assess pain during and after diagnostic hysteroscopy in patients of reproductive age according to use of vaginal misoprostol.

Design: A randomized, triple-masked, controlled clinical trial (Canadian Task Force classification I).

Setting: Diagnostic center at Instituto Materno Infantil de Pernambuco-Brazil.